Etropal ADXBUL:ETR 50 FCF Yield % is -0.59 as of Jul. 08, 2026. GuruFocus rates XBUL:ETR with a GF Score™ of 50/100 and a GF Value™ of €8.57 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 855 Medical Devices & Instruments companies, Etropal AD ranks worse than 50.99% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Etropal AD's FCF Yield % or its related term are showing as below:
XBUL:ETR'
s FCF Yield % Range Over the Past 10 Years
Min: -4.03 Med: 0.11 Max: 2.64
Current: -0.59
During the past 13 years, the highest FCF Yield % of Etropal AD was 2.64%. The lowest was -4.03%. And the median was 0.11%.
XBUL:ETR's FCF Yield % is ranked worse than 50.99% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: -0.38
vs XBUL:ETR: -0.59
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Etropal AD FCF Yield % Related Terms
Etropal AD FCF Yield % Historical Data
* Premium members only.
The historical data trend for Etropal AD's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XBUL:ETR vs ISRG, BDX, MDLN: FCF Yield % Comparison
For the Medical Instruments & Supplies subindustry, Etropal AD's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Etropal AD FCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Etropal AD's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Etropal AD's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Etropal AD (XBUL:ETR) has a FCF Yield % of -0.59 as of Jul. 08, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Etropal AD and its competitors. According to the industry distribution chart, Etropal AD ranks #436 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 51%.
Is Etropal AD's FCF Yield % too high?
Etropal AD's current FCF Yield % is -0.59. Based on the distribution chart, Etropal AD ranks #436 out of 855 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Etropal AD has a GF Score™ of 50/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Etropal AD's FCF Yield % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Etropal AD ranks #436 out of 855 companies for FCF Yield %. This places Etropal AD in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Devices & Instruments company?
A good FCF Yield % depends on the Medical Devices & Instruments industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Etropal AD and its competitors. Etropal AD's current FCF Yield % is -0.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Etropal AD stock overvalued right now?
Based on GuruFocus' analysis, Etropal AD (XBUL:ETR) is currently considered Significantly Undervalued. The stock's GF Value™ is €8.57, compared to a current price of €2.52 — trading 70.6% below its estimated fair value. The current FCF Yield % is -0.59. Etropal AD's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Etropal AD (XBUL:ETR), the current FCF Yield % is -0.59 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Etropal AD (XBUL:ETR) Overvalued in 2026?
Based on GuruFocus' analysis, Etropal AD stock appears to be undervalued.
The current stock price of €2.52 is trading 70.6% below its estimated GF Value™ of €8.57.
GuruFocus considers Etropal AD to be Significantly Undervalued.
Key valuation signals for XBUL:ETR:
FCF Yield %: -0.59
GF Value™: €8.57 vs. price of €2.52 (70.6% below fair value)
No single metric tells the full story. See the XBUL:ETR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Etropal AD is engaged in the business of manufacturing medical accessories. The product portfolio includes fistula needles, blood taking sets, transfusion and infusion sets, catheters and tubes, urine collecting bags, colostomy bags, among others. The company also produces hip - joint endoprosthesis and instruments of implantation.
50GF Score
Get the complete analysis for XBUL:ETR
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XBUL:ETR has been successfully added to your 
